CLL Therapy Approaches in Russia

Trial Identifier: D8220R00038
Sponsor:AstraZeneca
NCTID:NCT05140369
Start Date:October 2021
Primary Completion Date: October 2025
Study Completion Date: October 2025
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

CountryLocation
Russia Irkutsk, Russia
Russia Moscow, Russia
Russia Moscow, Russia
Russia Nizhniy Novgorod, Russia
Russia Novosibirsk, Russia
Russia Saint Petersburg, Russia